Cardinal Health, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Cardinal Health, Inc. stock analysis CAH overview
Somewhat Bullish +50

Jim Cramer on Cardinal Health: “I Want You to Buy It and Buy It, Get This, Aggressively”

📣 Jim Cramer urged investors to "buy aggressively" Cardinal Health (CAH) during a CNBC interview despite his previous admission of entering the position too early for some trusts.

💊 The host highlighted Cardinal Health's diversified business model, which includes distributing branded and generic medicines alongside medical and surgical products.

📈 While Cramer predicted significant upside potential, he noted that Cardinal Health stock had "fallen really hard," creating an opportunity for buyers.

💰 Financial data indicates CAH shares closed at $206.40 on March 23, 2026, with a 52-week gain of 55.48% despite a -8.66% one-month return.

🏛 Brown Advisory's fourth-quarter 2025 investor letter credited Cardinal Health as a leading contributor to their Mid-Cap Growth Strategy.

⚖️ Cardinal Health delivered a strong fiscal first quarter according to the firm, driven by improved specialty mix and continued margin recovery in its Medical segment.

🤖 The article includes promotional content suggesting that AI stocks may offer greater upside potential than traditional healthcare plays like Cardinal Health.

📊 Hedge fund sentiment remains positive with 60 portfolios holding Cardinal Health at the end of Q4 2026, up from 55 in the prior quarter.

🔄 Fiscal second quarter revenue for Cardinal Health increased 19% year-over-year to reach $66 billion according to the article's data.

📉 Brown Advisory acknowledged their strategy lagged the Russell Midcap Growth Index in Q4 2025 due to not holding Palantir Technologies (PLTR).

📰 The article was originally published by Insider Monkey and references external reports on dividend stocks and hedge fund investor letters.

⚠️ Renaissance Investment Management's Large Cap Growth Strategy underperformed the S&P 500 in Q4 2025 due to market concentration in AI mega-cap tech companies.

Bullish Signals
  • Jim Cramer recommended Cardinal Health (CAH) for aggressive buying, describing it as an 'amazing stock' that has improved since their last discussion despite falling hard.
  • Cramer specifically highlighted the urology purchase as a major positive catalyst and projected the stock could rise to $300.
  • Fiscal first quarter results were strong enough to prompt an early guidance increase with further upside potential following the margin- and net-accretive Solaris acquisition.
  • Cardinal Health delivered solid demand in nuclear and home health segments with continued margin recovery in Medical operations.
  • Hedge fund ownership increased, rising from 55 portfolios in the previous quarter to 60 hedge fund portfolios holding the stock by the end of the fourth quarter.
  • Second quarter of fiscal 2026 revenue increased 19% year-over-year to $66 billion, demonstrating robust growth trajectory.
  • The stock has gained 55.48% over the past 52 weeks with a market capitalization of $48.569 billion.
Risk Factors
  • Jim Cramer admitted he 'got too enthusiastic' about Cardinal Health and bought it 'too soon for the trust,' indicating a potential misjudgment of entry timing despite his bullish stance.
  • The stock fell significantly ('fell really hard') during Cramer's discussion, suggesting volatility or downward pressure prior to his recommendation.
  • Brown Advisory Mid-Cap Growth Strategy lagged the Russell Midcap® Growth Index in Q4 2025 due to stock selection issues, potentially impacting exposure to Cardinal Health within that portfolio.
  • Despite being a top contributor for Brown Advisory, Renaissance Investment Management underperformed the S&P 500 and Russell 1000 Growth Index in Q4 2025, highlighting broader market weakness affecting growth strategies.
  • Cardinal Health was notably absent from the list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026, despite 60 portfolios holding it at Q4 end.
  • One-month return for Cardinal Health stood at -8.66% as of March 23, 2026, indicating recent significant price depreciation.
  • Market capitalization reached $48.569 billion, which may suggest the stock is becoming less undervalued compared to earlier claims.
Full Analysis
Jim Cramer appeared on the latest episode of his show to discuss Cardinal Health, Inc. (NYSE:CAH), advising viewers to buy the stock aggressively amid concerns over rising energy costs and economic uncertainty. During a segment featuring caller Jason Hollar, who had previously recommended the company after its urology purchase, Cramer expressed strong enthusiasm for CAH, noting that he himself has started buying shares and believes the stock is "amazing" having fallen significantly from previous highs. Cramer suggested that Cardinal Health could reach a price point of $300 per share, citing no fundamental issues with the business and indicating it may be performing better than in previous discussions. Institutional investors have also recognized Cardinal Health's strength, with Brown Advisory highlighting it as a leading contributor in its Mid-Cap Growth Strategy for the fourth quarter of 2025. According to the firm’s investor letter, Cardinal Health delivered a strong fiscal first quarter driven by improved specialty mix in pharmaceuticals, solid demand in nuclear and home health sectors, and continued margin recovery in its medical division. The company raised guidance early, with Brown Advisory noting further upside potential linked to the Solaris acquisition, which they describe as margin- and net-accretive. Financial data indicates that on March 23, 2026, Cardinal Health stock closed at $206.40 per share, having gained 55.48% over the past 52 weeks despite a one-month return of -8.66%. The company operates with a market capitalization of $48.569 billion, distributing branded and generic medicines while providing pharmacy services and manufacturing surgical products. Hedge fund holdings reflect modest but positive sentiment toward Cardinal Health, with 60 hedge fund portfolios holding shares at the end of the fourth quarter compared to 55 in the previous quarter, up from a lower count prior. While Renaissance Investment Management reported that its Large Cap Growth Strategy underperformed due to market concentration in mega-cap technology companies during the fourth quarter of 2025, it acknowledged that healthcare distribution trends remained resilient. However, Insider Monkey and other sources note that while CAH is viewed as an investment with potential, certain AI stocks are currently seen as offering greater upside potential with less downside risk, particularly within a broader strategy focusing on undervalued positions benefiting from tariff policies and onshoring trends.